Matinas BioPharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall st set to open higher as chip stocks gain; US-Iran tensions in focus
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil eases as investors assess US-Iran peace prospects
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Matinas BioPharma (MTNB) Reports In-Line Q3 EPS
November 13, 2019 6:31 AM ESTMatinas BioPharma (NYSE: MTNB) reported Q3 EPS of ($0.03), in-line with the analyst estimate of ($0.03).
I am extremely pleased with the progress we made in the third quarter, positioning the Company to commence two important studies for our lead assets, MAT9001 and MAT2203, commented Jerome D. Jabbour, Chief Executive Officer of Matinas. With respect to MAT9001, we began pre-screening patients in... More
